CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
DRIVIN’ CAR aims to enhance cancer immunotherapy by creating a cost-effective platform for generating chimeric antigen receptor immune cells in the body. Utilizing advanced nanoparticle technology, it targets myeloid cells for improved therapy against solid tumors and has potential applications in autoimmune and cardio…
DRIVIN’ CAR aims to transform immunotherapy by developing a scalable, cost-effective platform for in vivo generation of chimeric antigen receptor (CAR) immune cells.
Using proprietary apolipoprotein nanoparticle (aNP) platform technology, DRIVIN’ CAR pursues robust CAR monocyte/macrophage (CAR M) and CAR T cell therapy.
Owing to their biocompatibility and natural tropism for myeloid cells, aNPs are excellently suited for in vivo CAR M therapy.
For efficient in vivo T cell targeting, aNPs can be…
TECHNISCHE UNIVERSITEIT EINDHOVEN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Netherlands, Eindhoven
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Belgium, Bruxelles / Brussel
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Germany, Aachen
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Netherlands, NIJMEGEN
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
